Ocugen Inc
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Ocugen Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Price history
Chart
Interactive price chart (TradingView).
52-week range: 0.994 $ to 2.50 $ · Last price: 1.00 $ (As of: September 25, 2026)
Key figures
Key figures at a glance
Every figure we hold for this stock, grouped by topic. The question mark next to a label explains what the number means.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 09/25/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Comparison
Industry comparison
The stock alongside the largest companies in the same group. The median row is the middle value of the companies shown above — not of the whole industry.
Industry: Biotechnology
| Company | Market cap ($B) | P/E | EV/EBITDA | Gross Margin % | EBIT Margin % | Sales Growth (Year) % | Perf. 1Y % |
|---|---|---|---|---|---|---|---|
| Ocugen Inc OCGN | 0.3 | – | -2.0 | -855.3 | -1,105.1 | 8.8 | -39.0 |
| Vertex Pharmaceuticals Inc VRTX | 133.1 | 31.9 | 24.4 | 55.0 | 38.1 | 9.6 | 37.8 |
| Regeneron Pharmaceuticals Inc REGN | 81.9 | 19.8 | 13.5 | 44.5 | 20.7 | 1.0 | 38.7 |
| Moderna Inc MRNA | 78.9 | – | 4.6 | -66.0 | -131.1 | -39.2 | 708.1 |
| argenx NV ARGX | 59.7 | 36.7 | 31.5 | 59.1 | 32.0 | 89.6 | 31.9 |
| Revolution Medicines Inc RVMD | 42.6 | – | -9.7 | -174,708.6 | 0.0 | -100.0 | 359.0 |
| BeiGene, Ltd. ONC | 40.8 | 64.4 | 32.4 | 88.9 | 19.1 | 40.2 | 9.1 |
| Alnylam Pharmaceuticals Inc ALNY | 34.0 | 64.4 | 28.6 | 79.7 | 23.0 | 65.2 | -45.6 |
| Royalty Pharma Plc RPRX | 32.1 | 31.4 | 19.2 | 95.8 | 100.3 | 5.1 | 70.0 |
| Median of companies shown | 42.6 | 34.3 | 19.2 | 55.0 | 20.7 | 8.8 | 37.8 |
Based on the most recently reported figures. Only stocks from the same trading venue are lined up, so the market caps are counted in one currency. Compare in a chart →
Fiscal years
Annual Figures
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
Revenue, operating income and net income per fiscal year $M
Revenue Operating income Net income
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 0 | -30 | -16 | -67.58 | -26 | 14 | 36 |
| 2017 | 0 | -25 | -26 | -69.91 | -23 | -11 | 11 |
| 2018 | 0 | -30 | -9 | -13.98 | -16 | 0 | 17 |
| 2019 | 0 | -14 | -20 | -1.46 | -17 | 11 | 17 |
| 2020 | 0 | -21 | -22 | -0.19 | -15 | 22 | 27 |
| 2021 | 0 | -58 | -58 | -0.30 | -48 | 96 | 106 |
| 2022 | 2 | -85 | -78 | -0.36 | -60 | 74 | 109 |
| 2023 | 6 | -66 | -63 | -0.26 | -62 | 41 | 65 |
| 2024 | 4 | -55 | -54 | -0.20 | -42 | 30 | 82 |
| 2025 | 4 | -63 | -68 | -0.23 | -57 | -12 | 44 |
Quarters
Quarterly Figures
Each bar is one quarter, the last one is the most recent. Use the switch to step through the individual figures.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q3 | -0.05 | 16.70 | 1 | -69.30 | -1,141.70 | -11 | -12 |
| 2024: Q4 | -0.05 | -66.70 | 1 | -87.30 | -1,816.80 | -10 | -10 |
| 2025: Q1 | -0.05 | 0.00 | 2 | 46.10 | -1,036.50 | -19 | -19 |
| 2025: Q2 | -0.05 | -25.00 | 1 | 20.30 | -1,073.50 | -11 | -11 |
| 2025: Q3 | -0.07 | -40.00 | 2 | 54.20 | -1,144.50 | -13 | -13 |
| 2025: Q4 | -0.06 | -20.00 | 0 | -125.30 | – | -14 | -14 |
| 2026: Q1 | -0.06 | -20.00 | 2 | 3.50 | -1,250.90 | -22 | -22 |
| 2026: Q2 | -0.07 | -40.00 | 2 | 8.40 | -1,671.80 | -13 | -13 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Screening
Appears in These Scanners
This stock currently matches 3 of our scanner strategies — each hit links to the scanner.
Breakout & Setup
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Outlook
Analysts & Price Target
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Distribution of Recommendations
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.24 | -0.28 – -0.18 | 5 | -4.4% | 3 |
| 12/31/2027 | -0.27 | -0.36 – -0.18 | 3 | -11.1% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Valuation
What is priced in?
Free cash flow over the past twelve months is negative, which rules out a serious reverse calculation. Any growth rate only makes a negative cash flow more negative; no present value comes out of it. What the price reflects here is therefore not a stream of cash flows, but the expectation that there will be one at all.
A simplified model calculation — not a forecast and not a recommendation.
AI classification
AI Rating
Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available.
Growth
Growth Score
Ten checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 21.0%
- More than 10% revenue growth is expected for the coming year -75.6%
- Share count grows by less than 3% a year 11.8%
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -1,286.2%
- Gross margin at 40% or higher and without meaningful erosion 45.9%
- Goodwill from acquisitions does not grow faster than revenue 0.0%
- Net debt below twice EBITDA failed
- Operating cash flow covers the profits of the last three years 24 m
- Return on capital at 15% or higher, or up versus two years ago -307.3%
- Insiders hold at least 10% or are net buyers 1.7%
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Quality check
AAQS
0/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% –
- Exp. sales growth 3Y > 5% -24.7%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% -24.7%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% –
- ROCE > 15% -307.3%
- Expected return > 10% -37.6%
View stocks with the full AAQS score · Read the methodology at AlleAktien
Source: fundamental data
Insiders
Insider Transactions
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character.
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 9, 2026 | Musunuri Shankar | Chief Executive Officer | Sell | 57,264 | 1.12 | 64,136 |
| Sep 9, 2026 | Musunuri Shankar | Chief Executive Officer | Sell | 468,727 | 1.12 | 524,974 |
The company
About the Company
Ocugen, Inc., ein biopharmazeutisches Unternehmen, konzentriert sich auf die Entdeckung, Entwicklung und Vermarktung neuartiger Gen- und Zelltherapien, Biologika und Impfstoffe zur Verbesserung der Patientengesundheit. Das Pipeline-Produkt des Unternehmens umfasst OCU400, einen neuartigen Gentherapie-Kandidaten, der die Netzhautintegrität und -funktion bei einer Reihe genetisch unterschiedlicher erblicher Netzhauterkrankungen wiederherstellt und sich derzeit in Phase-3-Studien zur Behandlung von Retinitis pigmentosa sowie in Phase-1/2-Studien zur Behandlung der Leberschen kongenitalen Amaurose befindet; OCU410, eine Gentherapie in Phase 1/2 zur Behandlung der trockenen altersbedingten Makuladegeneration (AMD); sowie OCU410ST, eine Gentherapie in Phase 1/2 zur Behandlung der Stargardt-Krankheit. Es ist an der Entwicklung von OCU200 beteiligt, einem neuartigen rekombinanten Fusionsprotein zur Behandlung von diabetischem Makulaödem, diabetischer Retinopathie und feuchter altersbedingter Makuladegeneration; sowie NeoCart, einem autologen aus Chondrozyten gewonnenen Neoknorpel zur Reparatur von Knieknorpelverletzungen bei Erwachsenen. Zudem entwickelt das Unternehmen OCU500, einen COVID-19-Impfstoff; OCU510, einen saisonalen quadrivalenten Grippeimpfstoff; sowie OCU520, einen Kombinationsimpfstoff gegen saisonale Grippe und COVID-19. Es hat Kooperationsvereinbarungen mit dem National Institute of Allergy and Infectious Diseases für frühe klinische Studien des OCU500-Programms sowie eine strategische Partnerschaft mit CanSino Biologics Inc. zur Herstellung seiner modifizierenden Gentherapie-Pipeline-Kandidaten. Das Unternehmen wurde 2013 gegründet und hat seinen Hauptsitz in Malvern, Pennsylvania.
- Employees
- 116
- Headquarters
- Malvern, PA
- Address
- 11 Great Valley Parkway, 19355 Malvern, United States
- Phone
- 484 328 4701
- Website
- ocugen.com
- IPO Date
- 12/03/2014
- ISIN
- US67577C1053
- Stock Split
- 1:60 on 09/30/2019
Management
| Name | Title | Birth Year |
|---|---|---|
| Shankar Musunuri M.B.A., Ph.D. | Co-Founder, CEO & Chairman | 1964 |
| Arun Upadhyay Ph.D. | Chief Scientific Officer and Head of Research & Development | 1982 |
| Rita Johnson-Greene M.B.A. | CFO & Principal Accounting Officer | 1977 |
| Paul Staid | Executive Vice President of Operations | – |
| John Kouch J.D. | General Counsel | – |
| Chris Clark | VP of Corporate Communications | – |
| Kristen Craft | Head of People & Culture | – |
| Vijay Tammara Ph.D. | Chief Development Officer | 1960 |
| Mohamed Genead M.D., M.Sc. | Chief Medical Officer | – |
| Jyothy Pillai M.S. | VP & Head of Regulatory & Quality | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Filings
Company Filings (8-K)
An 8-K is the filing a US company must use to disclose material events immediately — takeovers, changes at the top, major contracts or payment troubles, for instance. The links open the original document at the US Securities and Exchange Commission (SEC).
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.